mRNA Length: 4,489 nucleotides
Concentration: 1.0 mg/mL
Buffer: 1 mM Sodium Citrate, pH 6.4
Agarose Gel Mobility; Pass
Concentration ± 6%; Pass
Cas9 Nickase mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9) that contains a D10A amino acid substitution. This mRNA also contains a C-terminal nuclear localization signal followed by a HA tag.
Cas9 functions as part of the CRISPR (clustered regularly interspaced short palindromic repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform the DNA cleavage. While wild-type Cas9 creates a double stranded break at the target site, Cas9 nickase creates a single stranded break. This favors homology-directed repair and decreases the occurrence of non-homologous end joining.
This mRNA is capped using CleanCap®, TriLink's proprietary co-transcriptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, modified with 5-methoxyuridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.
Certificate(s) of Analysis
L-7207 is replacement product for L-6116.
Provided under a Limited License
granted by Broad, MIT, Harvard, Iowa, UTokyo and Rockefeller.
Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.